Peter Bhatt

Peter Bhatt contributed to the early characterization and clinical translation of PD-1 checkpoint biology that led to the development of anti-PD-1 therapies. His research in the late 1990s and 2000s helped characterize PD-1 expression on exhausted T cells and its role in regulating antitumor immunity. He participated in the translational studies that connected the PD-1 pathway discovery to the development of nivolumab. His contributions represent a key step in the remarkable journey from PD-1 biology to transformative cancer treatments.